{"product_id":"fulgentgenetics-pestle-analysis","title":"Fulgent PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political, economic, social, technological, legal, and environmental forces are shaping Fulgent’s strategic outlook—our concise PESTLE highlights key risks and opportunities you need to know; buy the full analysis for a detailed, actionable roadmap to inform investment decisions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal healthcare budget allocations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal healthcare allocations shape Fulgent’s addressable market: the FY2025 omnibus earmarked roughly $47.5 billion for CDC and $48.1 billion for NIH, with increased line-items for genomic research and surveillance boosting testing contract opportunities.\u003c\/p\u003e\n\u003cp\u003eCDC and NIH funding drives large-scale screening adoption—CDC’s expanded surveillance programs funded at +8% in 2024–25 increased demand for high-throughput infectious disease assays relevant to Fulgent.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, a federal pivot toward personalized medicine, including Cancer Moonshot and precision diagnostics grants, has opened specialized diagnostic revenue streams and public-private partnership funding for companies like Fulgent.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent’s global supply chain is exposed to US trade tensions; in 2024 the company derived roughly 35% of revenue from international markets, so tariffs on lab equipment or reagents—which rose up to 7.5% on select imports in recent US actions—could raise COGS and delay deliveries, risking margin pressure on FY2025 guidance of mid-single-digit operating margin expansion; active trade-policy navigation is therefore essential to operational stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational security and genomic data policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical scrutiny of genomic data storage has risen as 78% of US lawmakers supported 2024 bills tightening cross‑border data transfers after reports of foreign access risks; Fulgent faces stronger oversight over sharing with non‑trusted entities.\u003c\/p\u003e\n\u003cp\u003eNew federal frameworks—drafts in 2024 propose fines up to $5M and mandatory isolation of sensitive datasets—aim to shield citizens’ genomic privacy from adversarial nations, raising compliance costs for labs.\u003c\/p\u003e\n\u003cp\u003eTo retain federal certifications and participate in government contracts (\u0026gt;$120M federal genomics market in 2025), Fulgent must update data governance, implement air‑gapped controls and continuous audits to meet national security mandates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health infrastructure investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState and local government investments in diagnostic infrastructure—federal ARPA-H and CDC grants totaling over $2.3B in 2024—shape genetic testing access in underserved areas, directly affecting Fulgent’s market reach.\u003c\/p\u003e\n\u003cp\u003ePolitical pushes to expand Medicaid and public health programs increased demand for affordable testing; Medicaid enrollment rose ~4% in 2024, expanding payer pools.\u003c\/p\u003e\n\u003cp\u003eFulgent’s proprietary high-throughput sequencing lowers per-test costs (reported ASP reductions ~15% YoY in 2024), positioning it as a cost-effective partner for government initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;$2.3B public diagnostic grants (2024)\u003c\/li\u003e\n\u003cli\u003eMedicaid enrollment +4% (2024)\u003c\/li\u003e\n\u003cli\u003eFulgent ASPs down ~15% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory lobbying and advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political landscape for biotech is driven by lobbying over oversight of laboratory-developed tests; in 2024 industry groups increased advocacy spending to about $120m nationwide, influencing debates on FDA vs CMS jurisdiction.\u003c\/p\u003e\n\u003cp\u003eFulgent participates in coalitions to push policies balancing innovation with patient safety and diagnostic accuracy, aligning with peers after reporting $425.8m revenue in 2023.\u003c\/p\u003e\n\u003cp\u003eShifts in leadership at agencies like FDA or HHS can rapidly change enforcement of clinical standards, as seen in 2022–24 guidance reversals affecting LDT pathways.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndustry advocacy spending ~ $120m (2024)\u003c\/li\u003e\n\u003cli\u003eFulgent revenue $425.8m (2023)\u003c\/li\u003e\n\u003cli\u003eRegulatory shifts 2022–24 altered LDT enforcement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal funding fuels genomics growth as tariffs, regs and ASP cuts reshape market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal funding boosts genomic demand (CDC ~$47.5B, NIH ~$48.1B FY2025); trade tariffs (up to 7.5%) risk 35% international revenue; genomic data rules tightened after 2024 bills with potential $5M fines; public grants\/Medicaid expansion (+$2.3B grants; Medicaid +4% 2024) expand testing access, favoring Fulgent’s ASPs down ~15% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDC FY2025\u003c\/td\u003e\n\u003ctd\u003e$47.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2025\u003c\/td\u003e\n\u003ctd\u003e$48.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff peak\u003c\/td\u003e\n\u003ctd\u003e7.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrants (2024)\u003c\/td\u003e\n\u003ctd\u003e$2.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASPs YoY (2024)\u003c\/td\u003e\n\u003ctd\u003e-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Fulgent across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify risks and opportunities for executives and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Fulgent that’s ready to drop into presentations or planning sessions, enabling quick alignment across teams and supporting external risk discussions with clear, editable notes for regional or business-line context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe financial health of genetic testing firms like Fulgent hinges on reimbursement set by Medicare, Medicaid and private insurers; in 2024 CMS pricing changes cut some molecular pathology rates by up to 10-15%, pressuring industry gross margins that averaged ~35% for diagnostics firms in 2023. Fluctuations can swing Fulgent’s service margins materially, so management must continuously negotiate coverage and pricing to secure sustainable reimbursement for new and existing tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of capital and interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, US prime rate stood near 8.5% and 10-year Treasury yields averaged ~4.9%, raising Fulgent’s effective borrowing costs and constraining large-scale acquisitions or lab expansion timelines.\u003c\/p\u003e\n\u003cp\u003eHigher rates push management toward cautious capital expenditure; 2025 capex guidance remained conservative at under $30M to preserve liquidity.\u003c\/p\u003e\n\u003cp\u003eFulgent’s cash and short-term investments of roughly $220M at FY2025-end bolster its ability to sustain R\u0026amp;D despite tightening credit conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressure on laboratory supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising costs for specialized reagents, consumables and logistics—UP by ~12–18% YoY in 2024 for molecular diagnostics inputs—can compress Fulgent’s EBIT margins unless offset by efficiencies.\u003c\/p\u003e\n\u003cp\u003eFulgent’s proprietary automation and high-throughput platform reduced per-test cost by an estimated 20–30% in recent years, helping offset inflationary pressure on materials.\u003c\/p\u003e\n\u003cp\u003eMaintaining a resilient supply chain and strategic sourcing for sequencing reagents is essential to avoid episodic price shocks that could materially impact gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer discretionary spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns can reduce elective genetic testing demand—U.S. consumer health spending fell 3.4% in 2023 real terms, and Fulgent saw consumer-test volumes decline ~12% YoY in parts of 2023–24 for nonclinical panels.\u003c\/p\u003e\n\u003cp\u003eClinical diagnostics remain resilient; Medicare\/Medicaid and employer-covered testing supported a 2–4% CAGR in clinical lab revenue 2021–24, so Fulgent’s clinical mix cushions cyclicality.\u003c\/p\u003e\n\u003cp\u003eFulgent tracks unemployment, wage growth, and consumer confidence (U.S. CPI 2024 +3.4%, U.S. unemployment 3.9% early 2025) to optimize marketing spend toward premium elective services during stable income periods.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElective test volumes down ~12% YoY in 2023–24\u003c\/li\u003e\n\u003cli\u003eClinical revenues up ~2–4% CAGR 2021–24\u003c\/li\u003e\n\u003cli\u003eKey indicators monitored: unemployment, wage growth, CPI, consumer confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal currency fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Fulgent expands internationally, foreign exchange risk grows; a 10% USD appreciation in 2024 would have reduced reported revenues from non-USD markets by an estimated $8–12m given ~15% of 2024 revenue exposure outside the US.\u003c\/p\u003e\n\u003cp\u003eDollar strength can erode overseas price competitiveness, while weakness can boost repatriated margins; Fulgent reports using forward contracts and localized pricing to stabilize consolidated results, noting FX hedges covered roughly 60% of forecasted 2025 non-USD cash flows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~15% 2024 revenue from non-US markets\u003c\/li\u003e\n\u003cli\u003e10% USD move ≈ $8–12m revenue impact\u003c\/li\u003e\n\u003cli\u003eFX hedges cover ≈60% of 2025 non-USD cash flows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargins squeezed by CMS cuts \u0026amp; inflation; automation, $220M cash, FX hedges buffer risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReimbursement cuts (CMS 2024 −10–15%) and 2024–25 input inflation (+12–18%) pressured margins, partly offset by automation (per-test cost −20–30%); FY2025 cash ≈ $220M and conservative capex \u0026lt; $30M support R\u0026amp;D; US rates\/10Y (~8.5%\/4.9% in 2025) raised borrowing costs, constraining M\u0026amp;A; ~15% revenue ex-US with 10% USD move ≈ $8–12M impact, FX hedges ≈60% coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS cut (2024)\u003c\/td\u003e\n\u003ctd\u003e−10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e+12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation saving\u003c\/td\u003e\n\u003ctd\u003e−20–30%\/test\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash FY2025\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex guidance 2025\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$30M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rates \/ 10Y (2025)\u003c\/td\u003e\n\u003ctd\u003e8.5% \/ 4.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-US revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX sensitivity\u003c\/td\u003e\n\u003ctd\u003e10% USD ≈ $8–12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedge coverage (2025)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eFulgent PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Fulgent PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content and layout visible in this preview are the same document you’ll download immediately after payment.\u003c\/p\u003e\n\u003cp\u003eEverything displayed is part of the final product, giving you a complete, actionable PESTLE assessment of Fulgent with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751591391609,"sku":"fulgentgenetics-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fulgentgenetics-pestle-analysis.png?v=1772233182","url":"https:\/\/matrixbcg.com\/products\/fulgentgenetics-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}